Objective: Lipids and steroid hormones are closely linked. While cholesterol is the substrate for (placental) steroid hormone synthesis, steroid hormones regulate hepatic lipid production. The aim of this study was to quantify circulating steroid hormones and lipid metabolites, and to characterize their interactions in normal and pathological pregnancies with a focus on hepatic and placental pathologies. Methods: A total of 216 serum samples were analyzed. Group A consisted of 32 patients with uncomplicated pregnancies who were analyzed at three different time-points in pregnancy (from the first through the third trimester) and once post partum. Group B consisted of 36 patients (24th to 42nd week of gestation) with pregnancy pathologies (IUGR n = 10, preeclampsia n = 13, HELLP n = 6, intrahepatic cholestasis n = 7) and 31 controls with uncomplicated pregnancies. Steroid profiles including estradiol, progesterone, and dehydroepiandrosterone were measured by GC-MS and compared with lipid concentrations. Results: In Group A, cholesterol and triglycerides correlated positively with estradiol (cholesterol ρ = 0.50, triglycerides ρ = 0.57) and progesterone (ρ = 0.49, ρ = 0.53) and negatively with dehydroepiandrosterone (ρ = − 0.47, ρ = − 0.38). Smoking during pregnancy affected estradiol concentrations, leading to lower levels in the third trimester compared to non-smoking patients (p < 0.05). In Group B, cholesterol levels were found to be lower in IUGR pregnancies and in patients with HELLP syndrome compared to controls (p < 0.05). Steroid hormone concentrations of estradiol (p < 0.05) and progesterone (p < 0.01) were lower in pregnancies with IUGR. Discussion: Lipid and steroid levels were affected most in IUGR pregnancies, while only minor changes in concentrations were observed for other pregnancy-related disorders. Each of the ana-Zusammenfassung ! Zielsetzung: Lipide und Steroidhormone stehen in wechselseitiger Beziehung zueinander. Cholesterin ist Ausgangssubstanz für die (plazentare) Steroidhormonsynthese. Die Lipidproduktion in der Leber wird von Steroidhormonen reguliert. Ziel der Studie war es, die Konzentration von Steroidhormonen und Lipiden im Blut im Verlauf der Schwangerschaft und bei Schwangerschaftspathologien mit Beteiligung von Leber oder Plazenta zu quantifizieren. Methoden: 216 Serumproben wurden analysiert. Gruppe A bestand aus 32 Patientinnen mit unkomplizierter Schwangerschaft, denen zu drei Zeitpunkten im Schwangerschaftsverlauf sowie einmal postpartal Blut abgenommen wurde. Gruppe B bestand aus 36 Patientinnen (24.-42. SSW) mit Schwangerschaftspathologien (intrauterine Wachstumsrestriktion [IUGR] n = 10, Präeklampsie n = 13, HELLP-Syndrom n = 6, intrahepatische Cholestase n = 7) sowie 31 Frauen mit unkomplizierter Schwangerschaft. Ein Steroidprofil einschließlich Estradiol, Progesteron und Dehydroepiandrosteron wurde mit der Gaschromatografie-Massenspektrometrie (GC-MS) erstellt und mit Lipidkonzentrationen verglichen. Ergebnisse: In der Gruppe A korrelierten Cholesterin-und Triglyzeridwerte positiv mit Estradiol (Cholesterin ρ = 0,50, Triglyzeride ρ = 0,57) und Progesteron (ρ = 0,49, ρ = 0,53) und negativ mit Dehydroepiandrosteron (ρ = − 0,47, ρ = − 0,38). Rauchen während der Schwangerschaft führte zu niedrigeren Estradiolkonzentrationen im 3. Trimenon im Vergleich zu Nichtrauchern (p < 0,05). In der Gruppe B wies die IUGR-Gruppe deutlichste Veränderungen auf. Hier zeigten sich verglichen mit der Kontrollgruppe insbesondere Werte für Cholesterin, Estradiol (p < 0,05) und Progesteron (p < 0,01) erniedrigt. Diskussion: Jede der analysierten pathologischen Entitäten wies ein spezifisches Lipid-und Steroid-
Introduction ! Lipid metabolism and steroid hormone biosynthesis are intimately linked. The effects of estrogen on lipid and lipoprotein concentrations have been studied most extensively in postmenopausal hormone replacement therapy [1, 2] . Orally administered estrogens increase triglyceride (TG) synthesis and triglyceriderich very-low-density lipoprotein cholesterol (VLDL) release from the liver [3] . The inhibiting effect of estrogen on hepatic lipase activity contributes to a reduction of TG catabolism [4] . Moreover, estrogen modulates low-density-lipoprotein (LDL)-receptor expression, thus regulating receptor-mediated LDL elimination [5] . During pregnancy, hepatic lipid metabolism is regulated by and interacts with steroid hormones released by the placenta, the primary endocrine organ producing pregnancy steroids. Placental estradiol is predominately synthesized from dehydroepiandrosterone (DHEA) sulfate precursors, provided by maternal and fetal adrenal glands at a ratio of approximately 40 : 60 [6] . Progesterone, however, is mainly produced from cholesterol and pregnenolone obtained from the maternal bloodstream. ApoB-containing LDL particles are considered to be the main source of cholesterol for placental progesterone synthesis [7] . l " Fig. 1 shows a simplified interaction of lipids with the steroidogenic pathways of the materno-feto-placental unit. As the pregnancy progresses, lipid and steroid hormone concentrations change markedly. After an initial reduction in the first eight weeks of pregnancy, plasma lipid concentrations increase steadily towards term. From the first to the third trimester, serum triglyceride (TG) concentrations rise by almost 300%, which is at least partially attributable to the increase in circulating estrogen concentrations [8] . Total cholesterol (TC) and LDL levels rise by 25 -50 % and 70%, respectively [9] . As LDL levels rise, there is a steady increase in progesterone concentrations [10] . Evidence is accumulating that the balance between lipid and steroid hormone levels is essential for maintaining a normal pregnancy. This is borne out by the fact that pathological pregnancies have been associated with altered lipid and steroid hormone profiles [11] [12] [13] [14] [15] [16] , a topic which is specifically addressed here later on. Given the important interactions between maternal liver and the placenta/fetoplacental unit for the regulation of lipids and steroid hormone metabolism, we hypothesized that pregnancy pathologies involving the placenta and/or the liver could affect pregnancy-specific lipid and steroid hormone interactions. In the present study, we first aimed to correlate lipid and steroid hormone concentrations in maternal serum in women with normal pregnancies through longitudinal measurements of serum levels of lipids and estradiol, progesterone, DHEA, and a further set of 9 characteristic progesterone or estrogen precursors and metabolites using highly specific gas chromatography and mass spectrometry (GC-MS) methods in healthy pregnant women. Secondly, we aimed to identify specific changes in these parameters in pregnancies complicated by intrauterine growth restriction (IUGR), preeclampsia (PE), HELLP syndrome, or intrahepatic cholestasis in pregnancy (ICP) compared to levels measured in uncomplicated pregnancies at the same gestational age.
Material and Methods

!
The study was approved by the ethics committee of the Medical Faculty of the Rheinisch Westfaelische Technical University (RWTH) Aachen (EK 138/06, 119/08, 154/11). Written informed lyzed entities displayed specific changes. However, since the changes were most obvious in pregnancies complicated by IUGR and only minor changes were observed in pregnancies where patients had impaired liver function, our data suggests that placental rather than maternal hepatic function strongly determines lipid and steroid levels in pregnancy. 
Definitions of study group B
IUGR was defined in accordance with the ACOG guidelines and as described recently [13] . In brief, the following criteria had to be fulfilled: estimated fetal weight < 10th percentile, plus 1. deceleration of fetal growth rate > 40th percentile on serial measurements, or 2. elevated resistance index on umbilical artery Doppler sonography above the 95th percentile, or absent or reversed end-diastolic blood flow, or 3. fetal asymmetry (head-to-abdominal circumference ratio > 95th percentile), or 4. oligohydramnios (amniotic fluid index < 6 cm). Preeclampsia was defined in accordance with the ISSHP criteria and as described elsewhere [13] as follows: new onset of hypertension of more than 140/90 mmHg and proteinuria of more than 300 mg/d or at least 2+ with urine dip-stick. Patients who had additional complications such as IUGR or HELLP syndrome were specifically excluded from the PE group. HELLP syndrome was defined as recently described elsewhere [17, 18] and included upper abdominal pain together with confirmation of the following laboratory criteria in maternal serum analysis: hemolysis (haptoglobin levels below 30 mg/dL); elevated liver enzyme activity (AST, ALT, LDH) three standard devia-tions above the mean; and low platelet count (below 100 000 G/ L). ICP was defined as a clinical finding of pruritus together with increased bile acid concentrations in maternal serum analysis (above 10 µmol/L) and elevated liver enzyme activity (AST, ALT) above the reference values (> 35 U/L) [19] after HELLP syndrome was excluded. General exclusion criteria for case and control groups were multiple gestation, fetal anomalies, abnormal fetal karyotype, patients with clinical or biochemical signs of infection, positive TORCH screening results, maternal diabetes mellitus or other severe maternal metabolic disorders, preterm birth following complications other than IUGR, PE, or HELLP syndrome, and the pa-tientʼs withdrawal from the study. Blood samples were taken from women prior to or at least 5 days after administration of corticosteroids (betamethasone) to the mother for the induction of fetal lung maturity where clinically indicated. In line with previous publications [20] this did not result in significant differences in any of the tested parameters between patients who received betamethasone and those who did not (data not shown).
Serum analysis Lipid profile
Blinded analysis of serum TG, TC, LDL-C and HDL-C was performed by colorimetric enzymatic methods using an automated photometric measuring unit (Roche/Hitachi Modular P800, Roche Diagnostics, Basel, Switzerland; triglycerides GPO-PAP reagent, cholesterol CHOD-PAP reagent, LDL-C plus 2nd generation reagent, HDL-C plus 3rd generation reagent, Cobas ® , Roche/Hitachi, Mannheim, Germany). Measurement ranges were: TG = 4-1000 mg/dL, TC = 3-800 mg/dL, LDL-C = 3-550 mg/dL, and HDL-C = 3-120 mg/dL.
Steroid profile
Steroid metabolites (DHEA, estradiol, and progesterone metabolites) were quantified by GC-MS in plasma (100-1000 µl) using the following procedure [21] . Following an extraction step with 10 vol dichloromethane, steroids were extracted in the organic phase containing unconjugated steroids and derivatized with 100 µl methoxyamine-HCl (Pierce Biotechnology, Rockford, IL, USA) in pyridine for 1 h at 60°C. After evaporation under nitrogen, samples were incubated with100 µl trimethylsilyl imidazole (Pierce Biotechnology, Rockford, IL, USA) for 16 h at 100°C. The derivatives were purified by gel filtration on Lipidex-5000 columns (Perkin Elmer, Wellesley, MA, USA) and analyzed by GC-MS and selective ion monitoring (Agilent Technologies, Palo Alto, CA, USA). One characteristic ion was programmed for each steroid analyzed. A standard curve containing a mixture of known amounts of all steroids was performed for each extraction panel. Inter-assay variability was controlled using an aliquot of plasma pool and was below 10 %.
Statistics
Data analysis was carried out using the statistical package Prism Version 6.0e Software (GraphPad Software Inc., CA, USA). Clinical data are presented as means and 95 % confidence interval (95 % CI) if metric. Categorical data are presented as percentages. Continuous variables are expressed as median ± 95 % CI or as indicated in the respective figure. Correlations were analyzed by Spearmanʼs correlation coefficient. Kruskal-Wallis test followed by Dunnʼs comparison post hoc test were done to compare measured variables between groups where indicated. Categorical da-ta were analyzed by χ 2 test. Values of p < 0.05 were regarded as significant.
Results
! Group Alongitudinal study group
The clinical characteristics of the longitudinal study group are presented in l " Table 1 . Mean gestational age at blood sampling was the 11th, 27th, and 37th week of gestation, and 13 weeks post partum.
Lipid profile of study group A
Lipid concentrations over the course of pregnancy in non-smoking and non-obese patients are presented in l " Table 2 . Mean TG levels increased by 175 % from the first to the third trimester, fol-lowed by a drop post partum to early pregnancy values. TC levels increased by 60 % and dropped post partum, but were still 27 % higher than in early pregnancy. The increase in TC levels was attributed mainly to increasing LDL levels (85 %). LDL levels remained higher post partum compared to levels in early pregnancy. After an initial rise in HDL concentration by 28% from the first to the second sampling time-point, HDL levels dropped steadily to first trimester values post partum (l " Table 2 ). In the 13 breast-feeding patients HDL levels were significantly higher compared to the five non-breast-feeding patients (median 68 mg/dL [95 % CI 58-75] vs. 52 , p = 0.0247). This resulted in a significantly lower LDL/HDL ratio in the breast-feeding group ( 
Steroid profile of study group A
As expected, progesterone and estradiol levels reached their maximum levels after 34 weeks of gestation while DHEA dropped to its minimum level in the same time period (l " , p = 0.0239). Post partum, the steroid hormone concentrations did not differ from first trimester values, independently of whether or not the patients were still breastfeeding (data not shown). The extended metabolome profile differed significantly over the course of pregnancy in three of nine analytes: 3α,5α-tetrahydroprogesterone allopregnanolone, 20α-dihydro-3β,5α-tetrahydroprogesterone, and estriol. Those three metabolites increased as pregnancy progressed and were significantly higher in the third trimester compared to the first trimester and dropped post partum to the levels observed in the first trimester or lower (l " Table  2 ). Correlation analysis was done to quantify the association between lipid values and the primary steroid hormone targets. Lipid values were positively correlated to estradiol (TG ρ = 0.66, p < 0.0001; TC ρ = 0.53, p < 0.0001; LDL ρ = 0.42, p < 0.0001; HDL ρ = 0.21, p = 0.051) and progesterone concentrations (TG ρ = 0.57, p < 0.0001; TC ρ = 0.45, p < 0.0001; LDL ρ = 0.35, p < 0.001; HDL ρ = 0.24, p = 0.024) and negatively correlated to DHEA levels (TG ρ = − 0.31, p = 0.003; TC ρ = − 0.37, p < 0.0001; LDL ρ = − 0.33, p = 0.002; HDL ρ = − 0.21, p = 0.053).
Group Bcross-sectional study group with pathological pregnancies
The clinical characteristics of the cross-sectional study groups are presented in l " Table 3 . Outcome data are missing for one patient in the ICP group because she was lost to follow-up. Following the exclusion of smokers and obese patients, mean maternal age, BMI, and weeks of gestation at blood collection did not differ significantly between the study groups compared to the CTRL group 
Lipid profile of study group B
Lipid profiles of the different groups are summarized in l " Table  4 . Compared to the CTRL group, LDL concentrations were significantly lower in the IUGR group. TC levels were significantly lower in the IUGR and the HELLP groups. HDL levels were lower in the ICP group.
Steroid profile of study group B
Progesterone and estradiol concentrations were lower in the IUGR group compared to the CTRL group, but otherwise, no other significant differences were observed (l " Table 4 ). In the extended metabolome profile, significant group differences were found for three of nine steroid hormones (3α,5α-tetrahydro-progesterone allopregnanolone, 11-keto-progesterone, and estriol) as indicated in l " Table 4 . The importance of lipid [8, 22] and steroid hormone metabolism [23, 24] for the maintenance of pregnancy has long been known. However, the regulatory mechanisms leading to a hyperlipidemic state during pregnancy are still not fully understood. The maternal liver as a primary source of lipids and the fetoplacental unit as the most important source of steroid hormones are intimately involved. As such, we expected to see concerted changes in steroid hormone production and lipid availability. Contrary to this assumption, we observed a rather moderate correlation between lipid and steroid levels in pregnancy, suggesting that there are other factors which independently regulate both lipogenesis and steroidogenesis. Specifically, steroid and lipid hormone metabolism are compromised when affected by pathological processes. This was best observed when placental insufficiency reflected by IUGR was present, while only minor changes were observed in patients with hepatic involvement characterized by pathological liver function test, e.g. HELLP syndrome and ICP. Life-style factors such as smoking during pregnancy contribute at least in part to metabolic changes. In line with previous publications [25] we found estradiol concentrations to be lower in the third trimester in smokers compared to non-smokers, most likely because of a reduction in placental aromatase activity [26] . Other factors that have been reported to influence maternal lipid concentrations during pregnancy are pre-pregnancy BMI and ethnic origin. Schreuder et al. found a remarkable interaction between ethnicity and cholesterol or triglyceride values throughout gestation, with the highest interdependencies found in Turkish women while in Dutch women BMI had only minor effects [27] . In our study of patients of Caucasian, predominantly German, origin, a higher pre-pregnancy BMI significantly affected HDL concentrations in the first trimester and post partum. However, significant changes could not be observed as the pregnancy progressed, suggesting that the effect of BMI on lipid values is much less than the effect caused by the pregnancy itself.
In pregnancy pathologies, the most significant differences in lipid and steroid hormone levels were observed for IUGR. The lower maternal LDL cholesterol concentrations were in agreement with those of previous reports [28] . ApoB-containing LDL particles are regarded as the main source of cholesterol for placental steroid hormone synthesis [7] . Indeed, lower steroid hormone levels of progesterone, estradiol, estriol, and allopregnanolone (5α-pregnan-3α-ol-20-one) were found in the present study in the IUGR group compared to the CTRL group. Since cholesterol, especially LDL cholesterol, is essential for steroid hormone synthesis, the lower hormone concentrations can be regarded as secondary to low substrate levels. Levels of progesterone and allopregnanolone are highly correlated throughout pregnancy [29] . Allopregnanolone is a neuroactive metabolite of progesterone synthesized from 5α-dihydroprogesterone by the enzyme 3α-hydroxysteroid dehydrogenase. The potential role of neurosteroids in protecting and regulating neurodevelopmental processes in the fetal brain has been recognized recently [30, 31] , and this finding may offer a new direction for the treatment of neurodevelopmental disorders in infants who are exposed to perinatal insults and pathologies. Hence it would be of great interest to analyze concentrations of allopregnanolone in the fetal compartment in IUGR pregnancies. Lower 17β-estradiol concentrations have been shown to result in an increase in LDL-receptor expression in placental explant experiments [32] . Thus, our results of lower 17β-estradiol levels in patients with IUGR could explain the higher LDL-receptor mRNA expression previously observed in IUGR placentas [33] . This mechanism might be an attempt at compensation to ensure sufficient placental cholesterol supply [5] . However, since 17β-estradiol has anti-oxidative properties protecting LDL from oxidation within the placenta [34] , a lower 17β-estradiol concentration in addition to increasing LDL elimination from the maternal blood stream could subsequently lead to increased formation and accumulation of oxidized LDL particles [35] . Lower progesterone concentrations observed in IUGR contribute to the idea of lower cholesterol biosynthesis rates, either due to reduced placental function because of the toxic effects of oxidative products or as a result of a diminished concentration of native substrate, i.e. nonoxidized (LDL) cholesterol.
Recently we showed that LDL-C concentrations were reduced in women with IUGR even when they had the additional complication of PE, while women with PE but not IUGR had normal LDL levels [13] . It has been suggested that impaired placental function causes the changes in lipid profiles. It is therefore important to note that, in women with PE in whom IUGR was excluded, there were no significant changes in either lipid or steroid hormone levels apart from a 57 % higher mean 11-keto-progesterone concentration in the PE group compared to the CTRL group in the present study. This most likely reflects changes in placental 11β-HSD2 activity which primarily deactivate the 11-ketosteroid cortisol to protect the fetus from high cortisol levels [36, 37] . Increased TG levels have frequently been observed in women with PE [38] , but the issue is still discussed controversially [39] .
In the present study we only found a tendency towards higher TG concentrations in women with PE. One explanation for the discrepant TG levels in the different studies could be the inclusion of different subtypes and cohorts of PE. Obesity is one of the predisposing factors. In our study, after the exclusion of obese patients, we found that patients with PE were only borderline overweight compared to the CTRL group. Use of the terms "placental PE" and "maternal PE" have been proposed to underline the fact that different pathomechanisms are involved at different gestational ages at the onset of disease (e.g. before 34 WoG vs. after 34 WoG). However, a comparison of early-onset with late-onset PE did not result in differences (data not shown). HELLP syndrome is a life-threatening condition that has been shown to affect both the placenta and the liver. Hence, massive changes in lipid profiles would have been expected. Only a few studies have evaluated patients with HELLP syndrome. Wetzka et al. observed an increase in TG concentrations in the intermediate density lipoprotein fraction [11] . We found TC levels to be lower in the HELLP syndrome group compared to the CTRL group. Since steroid hormones are not affected, lower TC concentrations may be related to impaired hepatic lipogenesis. By contrast, higher LDL and lower HDL concentrations have been reported in the livers of women with ICP [14] , a finding which was partly confirmed by our own analysis. Since these changes could already be observed before the clinical onset of disease, they are most likely a cause rather than a consequence of disease [14] . Moreover, steroid hormones may play a role in the pathophysiology. Estradiol-17β-D-glucuronides, for example, have cholestastic properties [40] . Progesterone may play an even greater role in the pathogenesis of ICP. An increase in bile acids and AST has been observed in studies in which progesterone was given to prevent preterm birth [41] . However, in concert with the results presented here, total progesterone levels did not rise in the ICP group compared to the group with normal
pregnancies. An excess of monosulfate and disulfate progesterone metabolites have been reported in the serum and urine of women with ICP, which may reflect impaired excretion or abnormal synthesis of these metabolites [42] . The small sample sizes, especially for the ICP and HELLP syndrome groups, limit the interpretation of our results. Moreover, blood samples were not drawn under defined nutritional conditions. This might affect TG values but should only have a limited impact on cholesterol or steroid hormones. LDL, for example, has a residence time of several days, and short-term fluctuations can be ignored [22] . In clinical practice, impairment of steroid profiles is determined based on 24 h urine collection, since steroid hormone production follows a circadian rhythm and blood sampling only provides a snapshot of the changes occurring during the day. Circulating concentrations of steroids also do not necessarily mimic urinary excretion of steroids, given the tissue-specific inactivation/metabolism of steroids. Nevertheless, the strength of this study is its well-characterized patient cohort and the comparisons done in our cross-sectional analysis of pregnancy-related changes observed in the longitudinal study arm. The use of GC-MS resulted in a highly specific assessment of the steroid hormones of interest, avoiding the frequently observed cross-reactivity occurring with conventional ELISA-or RIA-based measurement techniques.
In conclusion, different pregnancy pathologies are associated with characteristic lipid and steroid hormone profiles. A very pronounced difference was observed in serum estradiol and progesterone concentrations in IUGR pregnancies. Interestingly, although the liver is the primary source of lipid synthesis, placental insufficiency is more likely to affect lipid and steroid hormone metabolism than pregnancy-related liver disease.
Our results suggest that more targeted research into lipid and steroid hormone metabolism in pregnancy pathologies, with a special focus on IUGR, is indicated.
